Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Don’t Look Up? Investors Call For Tweaks To Small Molecule Provisions In US Pricing Bill

Budget Neutral Fix Could Mean Continued Innovation

Executive Summary

Investors and pharma stakeholders scramble to extend the time period before small molecule drugs are subject to government mandated discounts as Senate drug pricing legislation moves toward a floor vote.

You may also be interested in...



Medicare Price ‘Negotiation’ Would Have Stymied Verzenio Advance In Early Cancer – Lilly’s Ricks

‘It takes longer than nine years’ to profit from small molecule drug R&D, company CEO maintains in arguments against the negotiation process, and its timelines, in the Senate drug pricing reform legislation.

Pricing Reform Advocates Poised For ‘Rearguard Action’ By Industry If Legislation Prevails

Patient advocates are optimistic that ‘historic bill’ establishing price negotiation, inflation rebates and a spending cap in Medicare will pass into law.

Obesity Drug Coverage In ACA Plans May Expand With Shift In Treatment Classification Standard

Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel